GSA Capital Partners LLP Takes $2.09 Million Position in Cencora, Inc. $COR

GSA Capital Partners LLP bought a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 6,177 shares of the company’s stock, valued at approximately $2,086,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Oakworth Capital Inc. bought a new stake in shares of Cencora in the 4th quarter valued at about $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora in the 4th quarter valued at about $27,000. Archer Investment Corp lifted its stake in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares during the last quarter. IAG Wealth Partners LLC bought a new stake in shares of Cencora in the 3rd quarter valued at about $30,000. Finally, Cloud Capital Management LLC bought a new stake in shares of Cencora in the 3rd quarter valued at about $31,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 1.6%

Shares of NYSE:COR opened at $266.03 on Wednesday. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The company has a market cap of $51.76 billion, a PE ratio of 20.40, a P/E/G ratio of 1.21 and a beta of 0.64. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The stock’s 50-day moving average is $310.87 and its 200 day moving average is $338.24.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the prior year, the firm earned $4.42 EPS. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.76 EPS for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio is 18.40%.

Wall Street Analyst Weigh In

COR has been the subject of a number of recent research reports. William Blair initiated coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating for the company. Morgan Stanley set a $342.00 price target on Cencora in a report on Friday, May 8th. Citigroup reduced their price target on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. Finally, Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.